HK Stock Market Move | REMGEN (09995) rose nearly 5% with 10 research studies unveiled at ESMO. Institutions are optimistic about its acceleration in overseas expansion.

REMEGEN (09995) rose nearly 5%, reaching 4.81% at the time of publication, to $96.95 Hong Kong dollars, with a turnover of $706 million Hong Kong dollars. On the news front, the 2025 European Society for Medical Oncology (ESMO) Annual Meeting will be held in Berlin, Germany from October 17th to 21st. This year's conference will feature 10 major studies from REMEGEN. Among them, the results of the RC48-C016 Phase III study of vedolizumab in first-line treatment of urothelial cancer were first announced at the conference's Chairman's Forum and simultaneously published in the New England Journal of Medicine. In addition, the Phase III clinical trial data of teprotumumab for the treatment of IgA nephropathy in China will be presented in the form of a "Late-Breaking Oral" report at the 2025 American Society of Nephrology (ASN) Annual Meeting, to be held in Houston, USA from November 5th to 9th. Huatai believes that the intensive data readouts fully confirm the global competitiveness of the company's pipeline and are expected to accelerate its overseas expansion: 1) Vedolizumab's Phase III trial is steadily progressing overseas, with the company expecting BLA for second-line treatment indications in early 2026; 2) RC148 has received CDEBTD, with overseas Phase I/II clinical trials approved by the FDA, showing potential for international market expansion; 3) Teprotumumab's global Phase III trial for myasthenia gravis is progressing smoothly, with primary Sjogren's syndrome expected to become the next key indication. They maintain a "buy" rating.